Aardvark Therapeutics, Inc. AARD
5.06
(0.49)
(8.83%)
as of 25 Sep
- Market cap
- $121.5M
- P/E
- 0.0×
Follow AARD
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
12.63 | 8.06 | 10.61 | 12.03 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.89 | 4.04 | 5.81 | 6.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.22 | 0.87 | 0.96 | 0.99 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.01 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.81) | (0.86) | (0.86) | (0.74) | |
Cash per Share |
3.38 | 4.18 | 5.61 | 5.82 | |
Shareholders Equity per Share |
3.42 | 3.99 | 5.43 | 5.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.42 | 3.99 | 5.43 | 5.64 | |
Free Cash Flow |
(17.60) | (18.87) | (16.81) | (16.13) | |
Working Capital |
74.27 | 81.98 | 101.34 | 118.47 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
74.00 | 81.98 | 101.34 | 118.36 | |
| Other line items | |||||
Quick Ratio |
11.57 | 7.86 | 10.43 | 11.77 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.81) | (0.86) | (0.86) | (0.74) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.57 | 3.52 | 2.19 | 2.74 | |
Average Assets |
114.47 | 127.81 | 97.34 | 66.61 | |
Average Common Equity |
105.86 | 118.84 | 26.00 | 43.79 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates